Neogen (NEOG) Stock Price, News & Analysis

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Neogen in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NEOG shares.
View NEOG analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12 month price objectives for Neogen's stock. Their NEOG share price targets range from $17.00 to $28.00. On average, they predict the company's share price to reach $22.50 in the next twelve months. This suggests a possible upside of 93.8% from the stock's current price.
View analysts price targets for NEOG or view top-rated stocks among Wall Street analysts.

Neogen's stock was trading at $20.11 at the beginning of the year. Since then, NEOG shares have decreased by 42.3% and is now trading at $11.61.
View the best growth stocks for 2024 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 25th 2024.
View our NEOG earnings forecast.

Neogen Co. (NASDAQ:NEOG) released its quarterly earnings data on Tuesday, April, 9th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.14 by $0.02. The company earned $228.80 million during the quarter, compared to analyst estimates of $230.01 million. Neogen had a net margin of 0.17% and a trailing twelve-month return on equity of 3.35%. The business's quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.12 EPS.

ETFs with the largest weight of Neogen (NASDAQ:NEOG) stock in their portfolio include iShares Emergent Food and AgTech Multisector ETF (IVEG), VanEck Agribusiness ETF (MOO), Franklin U.S. Small Cap Multifactor Index ETF (FLQS), Vanguard Russell 2000 Value ETF (VTWV) and Invesco S&P MidCap 400 GARP ETF (EWMC).Pacer BioThreat Strategy ETF (VIRS).

Shares of Neogen split on the morning of Tuesday, January 2nd 2018. The 4-3 split was announced on Friday, December 8th 2017. The newly created shares were payable to shareholders after the market closes on Friday, December 29th 2017. An investor that had 100 shares of stock prior to the split would have 133 shares after the split.

Neogen updated its FY 2024 earnings guidance on Tuesday, April, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $910.0 million-$920.0 million, compared to the consensus revenue estimate of $938.2 million.

31 employees have rated Neogen Chief Executive Officer John Adent on Glassdoor.com. John Adent has an approval rating of 56% among the company's employees. This puts John Adent in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neogen investors own include NVIDIA (NVDA), NIKE (NKE), Pfizer (PFE), AT&T (T), AbbVie (ABBV), Boeing (BA), JPMorgan Chase & Co. (JPM), W. P. Carey (WPC), Advanced Micro Devices (AMD) and Costco Wholesale (COST).

Neogen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include AMI Asset Management Corp (0.13%), Bridge City Capital LLC (0.08%), Sumitomo Mitsui Trust Holdings Inc. (0.04%), Northwest Investment Counselors LLC (0.03%), State of Michigan Retirement System (0.02%) and Diversified Trust Co (0.02%). Insiders that own company stock include Darci L Vetter, David H Naemura, Douglas Edward Jones, James C Borel, James P Tobin, Jason Warren Lilly, John Edward Adent, Ronald D Green, Steven J Quinlan, Terri A Morrical and William T Boehm.
View institutional ownership trends.

Shares of NEOG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.